Rigel Pharmaceuticals Earnings
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$0.87
Rigel Pharmaceuticals earnings summary
Rigel Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $0.87. In its most recent report on Aug 4, 2026 (Q2 2026), RIGL posted EPS of $0.88. Revenue for the quarter was $78.7 million.
Quarterly EPS is down 73.2% from the same quarter a year earlier. Across the last 16 reports, RIGL shares moved an average of 9.8% (in either direction) in the first trading session after results, rising 10 times and falling 6 times.
Summary generated from market data by MetaCap's automated system. Methodology
RIGL earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 4, 2026 | — | $0.88 | — | +6.0% |
| May 5, 2026 | — | $0.44 | — | +11.4% |
| Mar 3, 2026 | — | $14.11 | — | -10.1% |
| Nov 4, 2025 | — | $1.46 | — | +19.2% |
| Aug 5, 2025 | — | $3.28 | — | +24.6% |
| May 6, 2025 | — | $0.63 | — | +5.7% |
| Mar 4, 2025 | — | $0.82 | — | -1.9% |
| Nov 7, 2024 | — | $0.70 | — | +9.2% |
| Aug 6, 2024 | — | $-0.06 | — | +18.6% |
| May 7, 2024 | — | $-0.47 | — | -3.1% |
| Mar 5, 2024 | — | $-0.65 | — | -13.4% |
| Nov 7, 2023 | — | $-0.33 | — | +9.8% |
| Aug 1, 2023 | — | $-0.38 | — | -4.9% |
| May 2, 2023 | — | $-0.08 | — | +5.9% |
| Mar 7, 2023 | — | $-3.09 | — | -8.2% |
| Nov 3, 2022 | — | $-0.11 | — | +5.4% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.